Brief Description
Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, the company established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. The company developed CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and partnered with leading pharmaceutical companies to bring these important medicines to patients worldwide. In July 2018, Exelixis was added to the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.
Timeline
- 1994. Company founded
- 2000. Initial Public Offering on the NASDAQ stock exchange under the ticker symbol of EXEL
Inventors